Early Access — free while we kick the tires
EdgarHawk

TARA Protara Therapeutics, Inc. Insider Trading

1 filing analyzed · Latest 2025-05-16
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying

Historically, medium-priority insider buys have outperformed the S&P 500 by a median ~1% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 7,520, 2022-2026). Past results don't predict the future. How we measure this ↗

May 2025
2025-05-16
medium
20,000 shares
$63,800
@ $3.19
Significance 4/10

Director Levy buys 20,000 TARA shares at $3.19; stock down -52.2% from 52-week high.

Director Richard S Levy purchased 20,000 shares at $3.19, increasing his holdings by 64.5% from 31,000 to 51,000 shares in a company that is unprofitable with -$11.9M net income and only $2.9M quarterly revenue. The stock has declined -52.2% from its 52-week high of $6.67 and is down -20.2% over the past 30 days. Across all of Levy's open-market transactions, his prior 11 sells achieved a 90d well-timed rate of 9.09%, indicating generally poor timing on exits. This buy occurs against a backdrop of material weakness in both the stock price and company fundamentals, with the director substantially expanding his position despite recent downward momentum.

Insiders here also file at

More Chemicals and Allied Products companies

Get alerts for TARA

Add TARA to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access